These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 2624510)

  • 1. [Evaluation of ventricular function in patients treated with mitoxantrone and 4'-epidoxorubicin].
    Avilés A; Díaz-Maqueo JC; Arévila-Ceballos N; García Fernández R; López-Vancell D; Torras V
    Arch Inst Cardiol Mex; 1989; 59(6):615-8. PubMed ID: 2624510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of ventricular function by radionuclide angiography in patients receiving 4'-epidoxorubicin and mitoxantrone.
    Vorobiof DA; Iturralde M; Falkson G
    Cancer Chemother Pharmacol; 1985; 15(3):253-7. PubMed ID: 3863718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ventricular late potentials in the assessment of mitoxantrone cardiotoxicity.
    de Leonardis V; Bartalucci S; Cinelli P; De Scalzi M; Becucci A; Lottini G; Neri B
    Cardiology; 1991; 79(2):110-5. PubMed ID: 1933962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Echocardiographic evaluation of cardiotoxicity induced by anthracycline therapy].
    Okada Y; Horikawa K; Sano M
    Gan To Kagaku Ryoho; 1997 Mar; 24(5):585-9. PubMed ID: 9087292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radionuclide angiographic monitoring in patients treated with potentially cardiotoxic cytostatic drugs.
    Vorobiof DA; Falkson G; Iturralde MP
    S Afr Med J; 1988 Sep; 74(5):213-6. PubMed ID: 3166211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of ventricular function by echocardiography and radionuclide angiography in patients treated with mitoxantrone.
    Villani F; Galimberti M; Crippa F
    Drugs Exp Clin Res; 1989; 15(10):501-6. PubMed ID: 2632218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Isotopic ventriculography in the follow-up of cardiotoxicity induced by 4'epi-adriamycin].
    Casáns I; Lluch A; Jimeno J; Ciudad J; Losada A; García-Conde J; Belloch V
    Rev Esp Cardiol; 1988; 41 Suppl 2():89-96. PubMed ID: 3238152
    [No Abstract]   [Full Text] [Related]  

  • 8. The N-terminal pro-brain natriuretic peptide as a marker of mitoxantrone-induced cardiotoxicity in multiple sclerosis patients.
    Podlecka-Piętowska A; Kochanowski J; Zakrzewska-Pniewska B; Opolski G; Kwieciński H; Kamińska AM
    Neurol Neurochir Pol; 2014; 48(2):111-5. PubMed ID: 24821636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Left ventricular diastolic function with epirubicin therapy: an echodoppler study.
    Maione S; Giunta A; Itri F; Losardo L; Palma M; Giacummo A; De Blasio F; De Matteis L
    Int J Clin Pharmacol Ther Toxicol; 1992 Jun; 30(6):189-94. PubMed ID: 1612812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction.
    Daugaard G; Lassen U; Bie P; Pedersen EB; Jensen KT; Abildgaard U; Hesse B; Kjaer A
    Eur J Heart Fail; 2005 Jan; 7(1):87-93. PubMed ID: 15642537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can the epirubicin cardiotoxicity in cancer patients be prevented by angiotensin converting enzyme inhibitors?
    Radulescu D; Buzdugan E; Ciuleanu TE; Todor N; Stoicescu L
    J BUON; 2013; 18(4):1052-7. PubMed ID: 24344038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early epirubicin-induced myocardial dysfunction revealed by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers.
    Mercuro G; Cadeddu C; Piras A; Dessì M; Madeddu C; Deidda M; Serpe R; Massa E; Mantovani G
    Oncologist; 2007 Sep; 12(9):1124-33. PubMed ID: 17914082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model.
    Alderton PM; Gross J; Green MD
    Cancer Res; 1992 Jan; 52(1):194-201. PubMed ID: 1727379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term risk of leukaemia or cardiomyopathy after mitoxantrone therapy for multiple sclerosis.
    Mulroy E; Joyce E; Scott J; Melling J; Goggin C; Mahon N; O'Rourke K; Lynch T
    Eur Neurol; 2012; 67(1):45-7. PubMed ID: 22156316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid onset mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis.
    Avasarala JR; Cross AH; Clifford DB; Singer BA; Siegel BA; Abbey EE
    Mult Scler; 2003 Feb; 9(1):59-62. PubMed ID: 12617270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preliminary study on behaviour of atrial natriuretic factor in anthracycline-related cardiac toxicity.
    Neri B; De Scalzi M; De Leonardis V; Gemelli MT; Ghezzi P; Pacini P
    Int J Clin Pharmacol Res; 1991; 11(2):75-81. PubMed ID: 1831809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparative study of adriamycin, epirubicin and mitoxantrone in cancer of the breast. Review of the literature].
    Delozier T; Vernhes JC
    Bull Cancer; 1991 Nov; 78(11):1013-25. PubMed ID: 1369547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the myocardial performance index for early detection of mitoxantrone-induced cardiotoxicity in patients with multiple sclerosis.
    Pattoneri P; Pelà G; Montanari E; Pesci I; Moruzzi P; Borghetti A
    Eur J Echocardiogr; 2007 Mar; 8(2):144-50. PubMed ID: 16603413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of ventricular function by radionuclide angiography in patients receiving 4'-epidoxorubicin and mitoxantrone.
    Elisson O
    Cancer Chemother Pharmacol; 1986; 17(3):296-7. PubMed ID: 3461888
    [No Abstract]   [Full Text] [Related]  

  • 20. Cardiotoxicity evaluation in patients treated with a mitoxantrone combination as adjuvant chemotherapy for breast cancer.
    Fountzilas G; Afthonidis D; Geleris P; Salem N; Kottas G; Halkidis C; Apostolidis P; Beer M; Tourkantonis A
    Anticancer Res; 1992; 12(1):231-4. PubMed ID: 1567171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.